Kadmon (NYSE:KDMN) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Kadmon (NYSE:KDMN – Get Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

KDMN opened at $9.50 on Monday. Kadmon has a twelve month low of $3.19 and a twelve month high of $9.50. The business’s fifty day moving average price is $9.50.

About Kadmon (Get Rating)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Featured Articles

• Get a free copy of the StockNews.com research report on Kadmon (KDMN)
• MarketBeat: Week in Review 5/30 – 6/3
• Dividend Capture Strategy: What You Need to Know
• Okta On Verge Of Multi-Week Rally
• Xiaomi Co: Facing Macro Headwinds
• Don’t Bet On A Bounce For RH 

Want More Great Investing Ideas?